Search
Research
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observationThese findings may help to explain the decrease in external GW diagnoses seen in England.
Research
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsNo currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.
Research
Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trialViral respiratory infections are associated with significant morbidity and mortality.
Research
Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccineSuccessful defence against viral pathogens requires the rapid recognition of virus-specific "danger signals" and the activation of both innate and adaptive...
Research
Opportunities and challenges of the pulmonary route for vaccinationThe respiratory tract is an attractive target for the delivery of vaccine antigens.
Research
Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcusGroup B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...
News & Events
Video: Flu vaccine Q&AIt's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.
News & Events
The Kids Research Institute Australia research ensures kids are protected against whooping coughResearch by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.
Research
COVID-19 vaccine knowledge, attitudes, and experiences of health care workers in Perth, Western Australia: A qualitative studyHealth care workers (HCWs) faced an increased risk of Coronavirus Disease 2019 (COVID-19). Australia’s COVID-19 vaccine rollout commenced in February 2021 to priority groups, including HCWs. Given their increased risk, as well as influence on patients’ vaccine uptake, it was important that HCWs had a positive COVID-19 vaccination experience, as well as trusting the vaccine safety and efficacy data.
Research
Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021Within the first 4 months of the Western Australian COVID-19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.